Home » Stocks » Novartis

Novartis AG (NVS)

Stock Price: $84.93 USD 2.50 (3.03%)
Updated Aug 12, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 192.37B
Revenue (ttm) 49.53B
Net Income (ttm) 11.73B
Shares Out 2.29B
EPS (ttm) 3.14
PE Ratio 27.05
Forward PE 14.77
Dividend $3.09
Dividend Yield 3.64%

Stock Quote

Trading Day Aug 12, 2020
Last Price $84.93
Previous Close $82.43
Change ($) 2.50
Change (%) 3.03%
Day's Open 84.50
Day's Range 84.41 - 85.24
Day's Volume 1,882,429
52-Week Range 69.18 - 99.84

More Stats

Market Cap 192.37B
Enterprise Value 210.25B
Earnings Date (est) Oct 27, 2020
Ex-Dividend Date n/a
Shares Outstanding 2.29B
Float 2.14B
EPS (basic) 5.12
EPS (diluted) 3.14
FCF / Share 5.67
Dividend $3.09
Dividend Yield 3.64%
Earnings Yield 3.70%
FCF Yield 6.81%
Payout Ratio n/a
Shares Short 1.76M
Short Ratio 1.13
Short % of Float n/a
Beta 0.41
PE Ratio 27.05
Forward PE 14.77
P/FCF Ratio 14.68
PS Ratio 3.88
PB Ratio 3.55
Revenue 49.53B
Operating Income 7.06B
Net Income 11.73B
Free Cash Flow 13.10B
Net Cash -17.89B
Net Cash / Share -7.90
Gross Margin 70.02%
Operating Margin 14.24%
Profit Margin 24.10%
FCF Margin 26.46%
ROA 6.97%
ROE 13.68%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (22)

Buy 11
Overweight 3
Hold 6
Underweight 0
Sell 2

Analyst Consensus: Overweight

Price Target

(20.71% upside)
Current: $84.93
Target: 102.52
*Average 12-month price target from 18 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth5.59%6.21%-12.2%-1.89%-6.05%1.74%1.43%-12.47%15.15%-
Gross Profit34,25231,58929,77131,91632,98336,28936,13736,10540,39237,073
Operating Income7,0556,7746,7806,3416,9289,6989,77810,5649,58810,292
Net Income11,73212,6117,7036,71217,78310,2109,1759,2708,9409,794
Shares Outstanding2,3112,3172,3742,3742,3992,4262,4212,4072,2892,274
Earnings Per Share5.065.383.252.807.294.133.763.833.704.26
EPS Growth-5.95%65.54%16.07%-61.59%76.51%9.84%-1.83%3.51%-13.15%-
Dividend Per Share13.452.212.332.762.392.722.532.462.351.99
Dividend Growth509.52%-5.16%-15.75%15.71%-12.21%7.47%2.85%4.55%18.42%-
Operating Cash Flow13,62514,27212,62111,47511,89713,89713,17414,19414,30914,067
Capital Expenditures-522-1,152-1,234-1,701-2,130-2,564-2,855-2,376-2,106-1,642
Free Cash Flow13,10313,12011,3879,7749,76711,33310,31911,81812,20312,425
Cash & Equivalents11,44615,9649,4857,7775,44713,8629,2228,1195,0758,134
Total Debt29,33332,14828,53223,80221,93120,41118,01819,72620,22922,987
Net Cash / Debt-17,887-16,184-19,047-16,025-16,484-6,549-8,796-11,607-15,154-14,853
Book Value55,47478,61474,16874,83277,04670,76674,34369,13765,84463,196
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Novartis AG
Country Switzerland
Employees 110,000
CEO Vasant Narasimhan

Stock Information

Ticker Symbol NVS
Stock Exchange New York Stock Exchange
Sector Healthcare
Industry Drug Manufacturers—General
Unique Identifier NYSE: NVS
IPO Date November 18, 1991


Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. Its Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, established, and cardiovascular, renal and metabolism medicine products. The company's Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has collaboration agreements with Pear Therapeutics; Wyss Institute for Biologically Inspired Engineering at Harvard University and the Dana-Farber Cancer Institute; Science 37; Bill & Melinda Gates Foundation; Amgen; University of California, Berkeley; Bristol-Myers Squibb; Drugs for Neglected Diseases initiative (DNDi); TScan Therapeutics; and Dyno Therapeutics Inc. The company was founded in 1895 and is headquartered in Basel, Switzerland.